Advanced non‐small cell lung cancer (NSCLC) is a deadly disease with a dismal prognosis.1 However, a treatment strategy targeting the inhibition of driving mutations has revolutionized the survival in some patients.2 One specific patient group which has experienced a dramatic improvement in survival are those patients with anaplastic lymphoma kinase (ALK) fusion NSCLC who receive treatment with ALK tyrosine kinase inhibitors (ALKi). Here, ALK is linked to non-small cell lung carcinoma.